ACON
Aclarion, Inc. Common Stock NASDAQ Listed Apr 22, 2022$2.37
-3.07%
vs $2.44
Mkt Cap $6.8M
usd
52w Low $1.95
4.1% of range
52w High $12.03
50d MA $2.45
200d MA $3.21
P/E (TTM)
—
EV/EBITDA
—
P/B
0.4x
Debt/Equity
—
ROE
-56.4%
P/FCF
—
RSI (14)
44.70
ATR (14)
$0.17
Beta
—
50d MA
$2.45
200d MA
$3.21
Avg Volume
54.7K
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
8181 ARISTA PLACE · BROOMFIELD, CO 80021
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -1.05 | -1.12 | -6.7% | 2.35 | -1.3% | -2.6% | +3.1% | -3.4% | +1.8% | +3.4% | — |
| May 21, 2026 | AMC | -1.55 | -1.34 | +13.5% | 3.26 | -2.1% | -1.5% | -1.6% | -1.3% | +1.0% | +4.1% | — |
| Feb 25, 2026 | AMC | -3.60 | -3.60 | +0.0% | 2.68 | +0.0% | +0.0% | +2.2% | +4.4% | -6.3% | +15.7% | — |
| Nov 12, 2025 | AMC | -2.64 | -2.93 | -11.0% | 6.90 | -3.2% | -10.9% | +0.2% | -2.3% | +1.5% | -3.9% | — |
| Aug 14, 2025 | AMC | -2.26 | -2.75 | -21.7% | 7.16 | -1.5% | +2.2% | -0.5% | -3.6% | +0.4% | +3.1% | — |
| May 15, 2025 | AMC | -1447.20 | -9.32 | +99.4% | 6.90 | +1.3% | +0.6% | +3.3% | -3.1% | -1.2% | +1.6% | — |
| Mar 27, 2025 | AMC | -50.00 | -1551.93 | -3003.9% | 14.09 | -6.5% | -14.0% | -10.9% | +4.7% | +11.5% | -3.9% | — |
| Nov 14, 2024 | AMC | -1621.62 | -1351.35 | +16.7% | 153.68 | -5.8% | -3.9% | +7.0% | +1.0% | -0.1% | +1.4% | — |
| Aug 14, 2024 | AMC | -0.19 | -1351.35 | -9999.0% | 188.14 | -0.5% | +10.5% | -3.3% | +9.4% | -4.5% | -0.6% | — |
| May 15, 2024 | AMC | -0.57 | -3963.96 | -9999.0% | 251.45 | +0.7% | +18.0% | -1.1% | +0.1% | -4.6% | +7.7% | — |
| Apr 2, 2024 | AMC | -1.60 | -13865.09 | -9999.0% | 302.99 | -3.0% | -3.6% | -0.9% | +1.1% | -3.4% | -1.8% | — |
| Nov 14, 2023 | AMC | -13024.80 | -17297.30 | -32.8% | 49189.95 | +3.0% | -7.3% | +11.1% | -21.4% | -3.3% | +11.8% | — |
| Aug 25, 2023 | AMC | -0.09 | -25945.95 | -9999.0% | 65108.88 | +2.0% | +0.0% | -5.4% | +10.5% | +8.4% | -5.4% | — |
| Jul 3, 2023 | AMC | -0.10 | -0.15 | -50.0% | 102287.07 | +6.1% | +1.2% | +2.0% | -5.5% | +2.9% | -2.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25 | Ascendiant Capital | Maintains | Buy → Buy | — | $3.45 | $3.45 | +0.0% | -6.4% | +1.5% | -6.7% | +0.7% | +6.2% |
| Nov 20 | Ascendiant Capital | Maintains | Buy → Buy | — | $5.87 | $6.21 | +5.8% | +4.3% | -1.0% | +1.8% | -0.3% | +0.8% |
| Sep 19 | Ascendiant Capital | Maintains | Buy → Buy | — | $8.20 | $8.50 | +3.7% | +14.6% | -5.4% | -9.4% | -4.3% | +4.3% |
| Dec 13 | Maxim Group | Downgrade | Buy → Hold | — | $103.11 | $104.00 | +0.9% | -7.9% | +885.8% | -89.1% | +0.1% | +1.8% |
| Nov 27 | Ascendiant Capital | Maintains | Buy → Buy | — | $163.89 | $165.08 | +0.7% | -2.2% | +1.6% | +0.0% | -0.6% | +0.4% |
| Aug 26 | Ascendiant Capital | Maintains | Buy → Buy | — | $217.08 | $215.27 | -0.8% | +2.9% | -2.9% | -4.5% | -5.2% | -3.5% |
| Jul 6 | Maxim Group | Maintains | Buy → Buy | — | $128148.48 | $126918.36 | -1.0% | -0.6% | -3.5% | -0.1% | -3.1% | +22.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Williams Amanda MDir | — | Buy | 5,857 | $2.73 | $16K | 25,857 | -2.89% | -4.02% |
| Aug 14, 2026 | Gould Gregory AOff | CFO | Buy | 10,000 | $2.45 | $24K | 60,000 | +6.54% | -6.39% |
| Aug 13, 2026 | Ness BrentDir/Off | Chief Executive Officer | Buy | 5,234 | $2.31 | $12K | 111,534 | -6.14% | -1.84% |
| Aug 13, 2026 | Neal David KDir | — | Buy | 7,500 | $2.40 | $18K | 30,002 | -6.14% | -1.84% |
| Aug 13, 2026 | Wesemann WilliamDir | — | Buy | 2,150 | $2.34 | $5K | 23,713 | -6.14% | -1.84% |
| Aug 13, 2026 | Bond RyanDir | — | Buy | 21,122 | $2.37 | $50K | 76,122 | -6.14% | -1.84% |
| May 12, 2026 | Breidbart ScottDir | — | Buy | 5,664 | $3.18 | $18K | 5,664 | +4.13% | +0.00% |
| May 11, 2026 | Neal David KDir | — | Buy | 2,500 | $3.10 | $8K | 2,502 | +4.13% | +0.00% |
| May 11, 2026 | Ness BrentDir/Off | Chief Executive Officer | Buy | 6,289 | $3.18 | $20K | 6,300 | +1.61% | +1.27% |
8-K
Aclarion, Inc. -- 8-K Filing
Aclarion, Inc. appointed Gould as Chief Financial Officer, signaling leadership changes in the company's financial management structure.
Jun 4
8-K · 8.01
!! High
Aclarion, Inc. -- 8-K 8.01: Material Event / Announcement
Aclarion authorized a $2.5 million share repurchase program over the next 12 months, signaling management confidence in the stock's undervaluation.
Apr 22
Institutional (13F) — Top 7
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Captrust Financial Advisors | 14,559 | $48K | Added | Mar 2026 |
| 2 | Ubs Group Ag | 9,647 | $32K | Added | Mar 2026 |
| 3 | Bank Of Montreal /can/ | 10,000 | $29K | — | Jun 2026 |
| 4 | Vanguard Capital Management Llc | 6,782 | $20K | — | Jun 2026 |
| 5 | Clear Street Group Inc. | 103 | $297 | New | Jun 2026 |
| 6 | Caitong International Asset Management Co., Ltd | 4 | $12 | New | Jun 2026 |
| 7 | Danske Bank A/s | 1 | $3 | — | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 2
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 10,658 | $29K | Feb 2026 |
| 2 | Fidelity Series Total Market Index Fund | 477 | $2K | May 2026 |
Valuation
Market Cap
$6.8M
Enterprise Value
-$6.4M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
—
P/B
0.42x
P/S
64.44x
P/FCF
—
EV/EBITDA
—
Shares Out
2.3M
Financials (TTM)
Revenue
$84K
Net Income
-$9.2M
EBITDA
-$9.0M
Free Cash Flow
—
Op Cash Flow
—
EPS Basic
$-13.61
EPS Diluted
$-7.60
EPS Forward
—
Gross Margin
-51.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$13.7M
Total Liab.
$837K
Total Equity
—
Cash
$12.0M
LT Debt
—
Book Value/Sh
$5.62
Debt/Equity
—
Current Ratio
14.81
Quick Ratio
—
Returns & Growth
ROE
-56.4%
ROA
-52.9%
ROIC
—
Rev Growth YoY
—
EPS Growth YoY
—
Price Returns
2W
-7.6%
1M
+5.6%
3M
-21.0%
6M
-31.7%
12M
-67.4%
Technicals
52W High
$12.03
52W Low
$1.95
50d MA
$2.45
200d MA
$3.21
RSI (14)
44.70
ATR (14)
$0.17
Beta
—
Avg Volume
55K
Dividends
Div Rate
—
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 24, 2026 10:40am
· Source: financialmodelingprep.com